6505--Pluvicto
Award Notice Posted
- Solicitation number
- 36C25226AP1352
- Agency
-
Veterans Integrated Service Network 12
Veterans Health Administration, Department of Veterans Affairs
- Awarded
- to Novartis Pharmaceuticals Corporation
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 36F79720D018036C25226N0246 Federal contract award
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs, Veterans Integrated Service Network 12, awarded contract 36F79720D0180/36C25226N0246 to Novartis Pharmaceuticals Corporation on January 29, 2026, for the supply of Pluvicto, a specialized radiopharmaceutical product used to treat metastatic castration-resistant prostate cancer. The contract was valued at $685,885.20 and covers a six-month supply of the medication for the Jesse Brown VA Medical Center in Chicago, Illinois. This award was made under a limited sources justification, as Pluvicto is the first and only broadly available FDA-approved prostate-specific membrane antigen (PSMA) treatment in its class, making Novartis Pharmaceuticals the sole source capable of providing the required supplies. The procurement was completed through the General Services Administration Federal Supply Schedule, with pricing already determined to be fair and reasonable by the GSA.
Notice text
Awarded contract 36F79720D018036C25226N0246 to Novartis Pharmaceuticals Corporation for 685885.20 on 2026-01-29.
Files
| File | Type | Posted |
|---|---|---|
| P03 - Limiting_Sources_Justification_OVER_SAT - Pluvicto - signed 1.1.pdf | ||
| 36F79720D0180 36C25226N0246_1.docx | DOCX document |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity